Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay

Diabetes Care

Volumn 35, Issue 3, 2012, Pages 465-470

  Wang, Limei ^a   Lovejoy, Nicholas Fraser ^a   Faustman, Denise L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C PEPTIDE; INSULIN; UNCLASSIFIED DRUG; ZINC TRANSPORTER 8 AUTOANTIBODY;

ADOLESCENT; ADULT; AGE; AGED; ANTIBODY TITER; ARTICLE; ASSAY; C PEPTIDE BLOOD LEVEL; CELL FUNCTION; CHILD; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SYNTHESIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PANCREAS ISLET BETA CELL; PEPTIDE SYNTHESIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REFERENCE VALUE; SENSITIVITY ANALYSIS; SEX;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL ASSAY; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84859059508     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1236     Document Type: Article

References (23)

1. Gianani R, Campbell-Thompson M, Sarkar SA, et al. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia 2010;53:690-698
2. Madsbad S, Krarup T, Regeur L, Faber OK, Binder C. Insulin secretory reserve ininsulin dependent patients at time of diagnosis and the first 180 days of insulin treatment. Acta Endocrinol (Copenh) 1980;95:359-363 (Pubitemid 11211731)
3. Steele C, Hagopian WA, Gitelman S, et al. Insulin secretion in type 1 diabetes. Diabetes 2004;53:426-433
4. Eff Ch, Faber O, Deckert T. Persistent insulin secretion, assessed by plasma C-peptide estimation in long-term juvenile diabetics with a low insulin requirement. Diabetologia 1978;15:169-172 (Pubitemid 9011563)
5. Nakanishi K, Watanabe C. Rate of β-cell destruction in type 1 diabetes influences the development of diabetic retinopathy: protective effect of residual β-cell function for more than 10 years. J Clin Endocrinol Metab 2008;93:4759-4766
6. Liu EH, Digon BJ, Hirshberg B, et al. Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft. Diabetologia 2009;52: 1369-1380
7. Madsbad S, Faber OK, Binder C, McNair P, Christiansen C, Transbøl I. Prevalence ofresidual beta-cell function in insulindependent diabetics in relation to age at onset and duration of diabetes. Diabetes 1978;27(Suppl 1):262-264 (Pubitemid 8303583)
8. Sjöberg S, Gunnarsson R, Gjötterberg M, Lefvert AK, Persson A, Ostman J. Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-termtype 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987;30:208-213 (Pubitemid 17068507)
9. Panero F, Novelli G, Zucco C, et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 2009;32:301-305
10. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998;128:517-523
11. Steffes MW, Sibley S, Jackson M, Thomas W. β-Cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836 (Pubitemid 36929351)
12. Sochett EB, Daneman D, Clarson C, Ehrlich RM. Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children. Diabetologia 1987; 30:453-459 (Pubitemid 17139071)
13. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987;65:30-36
14. Kobayashi T, Nakanishi K, Sugimoto T, et al. Maleness asrisk factor for slowly progressive IDDM. Diabetes Care 1989; 12:7-11 (Pubitemid 19029808)
15. Mortensen HB, Swift PGF, Holl RW, et al.; Hvidoere Study Group on Childhood Diabetes. Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12months after diagnosis. Pediatr Diabetes 2010;11:218-226
16. Jaeger C, Allendörfer J, Hatziagelaki E, et al. Persistent GAD 65antibodies in longstanding IDDM are not associated with residual beta-cell function, neuropathy or HLA-DR status. Horm Metab Res 1997;29:510-515 (Pubitemid 27496348)
17. Achenbach P, Lampasona V, Landherr U, et al. Autoantibodies tozinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 2009;52: 1881-1888
18. Brorsson C, Vaziri-Sani F, Bergholdt R, et al.; Danish Study Group of Childhood Diabetes. Correlations between islet autoantibody specificity and the SLC30A8 genotype with HLA-DQB1 and metabolic control in new onset type 1 diabetes. Autoimmunity 2011;44:107-114
19. Wenzlau JM, Walter M, Gardner TJ, et al. Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects. J Clin Endocrinol Metab 2010;95:4712-4719
20. Sherry NA, Tsai EB, Herold KC. Natural history of β-cell function in type 1 diabetes. Diabetes 2005;54(Suppl. 2):S32-S39 (Pubitemid 43343329)
21. Pacini G, Beccaro F, Valerio A, Nosadini R, Crepaldi G. Reduced beta-cell secretion and insulin hepatic extraction in healthy elderly subjects. J Am Geriatr Soc 1990; 38:1283-1289
22. Akirav E, Kushner JA, Herold KC. Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes 2008;57:2883-2888
23. Keenan H, Sun JK, Levine J, et al. Residual insulin production and pancreatic β-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010; 59:2846-2853